Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)
Status:
Completed
Trial end date:
2012-04-19
Target enrollment:
Participant gender:
Summary
The primary purpose of this clinical study is to determine the recommended clinical doses of
vorinostat (MK-0683) and bortezomib administered in combination to participants with relapsed
and/or refractory multiple myeloma (MM). It was hypothesized that administration of
vorinostat in combination with bortezomib is sufficiently safe and tolerated well enough to
permit further study in participants with relapsed and/or refractory MM. Study results are
based on data collected up to the data cut-off date of 20-March-2011.